F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies that target the immune system, has appointed Dr Eliot Forster as CEO. Dr Forster succeeds former CEO Dr John Haurum. Eliot brings more than 25 years of extensive leadership experience in clinical-stage biopharmaceutical companies. Most recently, he served as CEO of Immunocore where he successfully steered the company’s strategy in immuno-oncology (IO), raising a $320M Series A and establishing clinical
collaborations with global pharmaceutical companies including AstraZeneca, GSK and Roche. Prior to Immunocore, Eliot held senior leadership positions at Pfizer (including Head of EU Development & Operations) and GSK.
